USAID's $422M contract for PEPFAR drug distribution in Kenya awarded to Chemonics International

Contract Overview

Contract Amount: $422,465,621 ($422.5M)

Contractor: Chemonics International, Inc.

Awarding Agency: Agency for International Development

Start Date: 2009-02-03

End Date: 2015-09-30

Contract Duration: 2,430 days

Daily Burn Rate: $173.9K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 3

Pricing Type: COST PLUS AWARD FEE

Sector: Healthcare

Official Description: TO PROCURE AND DISTRIBUTE ANTIRETROVIRAL, OPPORTUNISTIC INFECTION DRUGS AND OTHER SUPPLIES IN SUPPORT OF PEPFAR ACTIVITIES IN KENYATAS::19 1031::TAS

Plain-Language Summary

Agency for International Development obligated $422.5 million to CHEMONICS INTERNATIONAL, INC. for work described as: TO PROCURE AND DISTRIBUTE ANTIRETROVIRAL, OPPORTUNISTIC INFECTION DRUGS AND OTHER SUPPLIES IN SUPPORT OF PEPFAR ACTIVITIES IN KENYATAS::19 1031::TAS Key points: 1. Contract aimed to procure and distribute essential medicines for HIV/AIDS prevention and treatment. 2. Significant investment in public health infrastructure and disease control in Kenya. 3. Long-term contract duration suggests a sustained commitment to PEPFAR objectives. 4. Awarded via full and open competition, indicating a broad market search. 5. Contract type (Cost Plus Award Fee) allows for performance-based incentives. 6. Focus on antiretroviral and opportunistic infection drugs highlights critical health needs.

Value Assessment

Rating: good

The total award amount of $422.5 million over approximately 6.7 years represents a substantial investment in public health. Benchmarking this against similar large-scale pharmaceutical procurement and distribution contracts for global health initiatives is complex due to varying scopes and regions. However, the cost-plus-award-fee structure suggests an attempt to incentivize efficient performance and value for money, which is a positive indicator. Without detailed cost breakdowns and performance metrics, a precise value-for-money assessment is challenging, but the scale and duration imply a significant, ongoing need being addressed.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, suggesting that multiple qualified vendors had the opportunity to bid. The presence of three bidders indicates a competitive environment, which typically drives better pricing and service offerings. The specific details of the bidding process, including the number of proposals received and the evaluation criteria, would provide further insight into the effectiveness of the competition in securing optimal value for the government.

Taxpayer Impact: Full and open competition generally benefits taxpayers by fostering a market where contractors compete on price and performance, leading to potentially lower costs and higher quality services.

Public Impact

Beneficiaries include individuals in Kenya requiring antiretroviral and opportunistic infection drugs for HIV/AIDS management. Services delivered encompass the procurement, warehousing, and distribution of critical medical supplies. Geographic impact is national, covering all regions within Kenya where PEPFAR activities are implemented. Workforce implications include support for local logistics and healthcare personnel involved in drug distribution and patient care.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for cost overruns inherent in Cost Plus Award Fee contracts if not managed rigorously.
Dependence on a single large contractor for critical health supplies could pose supply chain risks.
Ensuring equitable distribution across all regions of Kenya may present logistical challenges.
Effectiveness of award fee structure in truly driving superior performance needs ongoing monitoring.

Positive Signals

Long-term commitment demonstrates sustained support for critical public health programs.
Full and open competition suggests a robust process for selecting the most capable vendor.
Focus on essential medicines addresses a fundamental need for HIV/AIDS treatment and prevention.
The scale of the contract indicates a significant effort to impact public health outcomes in Kenya.

Sector Analysis

This contract falls within the broader healthcare and public health sector, specifically focusing on pharmaceutical supply chain management for global health initiatives like PEPFAR. The market for such services involves large pharmaceutical distributors, logistics providers, and public health implementers. Comparable spending benchmarks would typically be found in other USAID or global health funding mechanisms for similar procurements in other countries, often running into hundreds of millions of dollars for multi-year, large-scale operations.

Small Business Impact

The provided data indicates that small business participation (sb) was false, and there was no specific small business set-aside (ss). This suggests the contract was not specifically targeted towards small businesses. While Chemonics International is a large company, the implications for subcontracting to small businesses are not detailed here. A thorough analysis would require examining the subcontracting plan and actual performance to assess the extent to which small businesses were involved in fulfilling the contract's requirements.

Oversight & Accountability

Oversight for this contract would primarily fall under the Agency for International Development (USAID), likely through its contracting officers and program managers. Accountability measures are embedded in the Cost Plus Award Fee structure, which allows for adjustments based on performance. Transparency is generally facilitated through contract award databases and reporting requirements. The Inspector General's office within USAID would have jurisdiction to investigate any allegations of fraud, waste, or abuse related to this contract.

Related Government Programs

PEPFAR (President's Emergency Plan for AIDS Relief)
Global Health Supply Chain
USAID Pharmaceutical Procurement
HIV/AIDS Drug Distribution Programs

Risk Flags

Supply Chain Risk
Performance Management
Cost Control
Drug Quality Assurance

Frequently Asked Questions

What is this federal contract paying for?

Agency for International Development awarded $422.5 million to CHEMONICS INTERNATIONAL, INC.. TO PROCURE AND DISTRIBUTE ANTIRETROVIRAL, OPPORTUNISTIC INFECTION DRUGS AND OTHER SUPPLIES IN SUPPORT OF PEPFAR ACTIVITIES IN KENYATAS::19 1031::TAS

Who is the contractor on this award?

The obligated recipient is CHEMONICS INTERNATIONAL, INC..

Which agency awarded this contract?

Awarding agency: Agency for International Development (Agency for International Development).

What is the total obligated amount?

The obligated amount is $422.5 million.

What is the period of performance?

Start: 2009-02-03. End: 2015-09-30.

What is the track record of Chemonics International in managing large-scale global health supply chain contracts?

Chemonics International has a significant track record in managing large-scale global health and development projects, including complex supply chain operations for organizations like USAID. They have been a major implementer for various health programs, often involving the procurement and distribution of pharmaceuticals and medical supplies in challenging environments. Their experience spans numerous countries and disease areas, including significant work related to HIV/AIDS through programs like PEPFAR. While their extensive experience is a positive indicator, the success of any specific contract depends on detailed execution, management, and oversight. Reviews of past performance, including any challenges or successes in similar large-scale distribution contracts, would provide a more granular understanding of their capabilities and potential risks.

How does the cost of this contract compare to similar PEPFAR drug distribution efforts in other countries?

Directly comparing the cost of this $422.5 million contract to similar PEPFAR drug distribution efforts in other countries is challenging without access to detailed cost breakdowns and specific contract scopes. Factors such as the volume of drugs procured, the complexity of the distribution network, the duration of the contract, local operating costs, and the specific health challenges of each country significantly influence total contract value. PEPFAR programs are large and varied, and while this contract represents a substantial investment, its cost-effectiveness should be evaluated relative to the specific needs and context of Kenya. Benchmarking would ideally involve comparing cost-per-unit metrics for key drugs or cost-per-person reached, adjusted for country-specific factors.

What are the primary risks associated with a contract of this magnitude and duration for pharmaceutical distribution?

Contracts of this magnitude and duration for pharmaceutical distribution carry several primary risks. Supply chain disruptions, whether due to logistical failures, political instability, or unforeseen global events (like pandemics), can impede the timely delivery of essential medicines. Counterfeit or substandard drugs entering the supply chain pose a significant risk to patient safety and program efficacy. Furthermore, managing a large budget over an extended period increases the risk of cost overruns if not meticulously controlled. There's also the risk of contractor performance degradation over time or a failure to adapt to evolving public health needs. Ensuring robust quality control, secure logistics, and effective performance monitoring are crucial to mitigating these risks.

How effective has PEPFAR been in Kenya, and how does this contract contribute to its overall goals?

PEPFAR has been instrumental in transforming the HIV/AIDS landscape in Kenya, significantly increasing access to prevention, treatment, and care services. The program has contributed to a reduction in HIV-related deaths and new infections, and has strengthened the country's health system. This specific contract, focused on procuring and distributing antiretroviral and opportunistic infection drugs, directly supports PEPFAR's core mission by ensuring that life-saving medications are available to those who need them. By maintaining a reliable supply chain for these critical drugs, the contract enables the continuity of treatment for hundreds of thousands of Kenyans living with HIV, thereby contributing directly to the program's goals of controlling the epidemic and improving health outcomes.

What historical spending patterns exist for pharmaceutical procurement and distribution under PEPFAR in Kenya?

Historical spending patterns for pharmaceutical procurement and distribution under PEPFAR in Kenya have generally shown a consistent and significant investment over the years, reflecting the ongoing need for HIV/AIDS treatment and prevention commodities. Prior to this large definitive contract, spending may have been distributed across multiple smaller contracts or mechanisms. The trend has been towards consolidating procurement and distribution efforts to achieve economies of scale and improve efficiency, as seen with this contract awarded in 2009. Overall, PEPFAR funding for commodities in Kenya has remained substantial, fluctuating based on program needs, funding levels, and strategic shifts within the global health landscape. This contract represents a major allocation within those historical patterns.

Industry Classification

NAICS: Public Administration › Administration of Human Resource Programs › Administration of Public Health Programs

Product/Service Code: MEDICAL SERVICES › GENERAL HEALTH CARE SERVICES

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Offers Received: 3

Pricing Type: COST PLUS AWARD FEE (R)

Evaluated Preference: NONE

Contractor Details

Address: 1717 H ST NW STE 1, WASHINGTON, DC, 20006

Business Categories: Category Business, Not Designated a Small Business, Subchapter S Corporation

Financial Breakdown

Contract Ceiling: $422,465,621

Exercised Options: $422,465,621

Current Obligation: $422,465,621

Contract Characteristics

Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline